Sofia Touami
CIK: 0002159567
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
LYCA
Lycia Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
About Touami Sofia
Touami Sofia (SEC CIK 0002159567) files insider reports with the SEC as Chief Business Officer of Lycia Therapeutics, Inc. (LYCA).
Signal8 holds 2 ownership filings by Touami Sofia (1 Form 3, 1 Form 4), filed between Oct 22, 2026 and Oct 26, 2026. Those filings report 1 transaction, the latest on Aug 11, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Touami Sofia's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Touami Sofia
- Aug 11, 2026: Grant or award of LYCA derivative securities (Form 4, code A).
Other insiders filing for Lycia Therapeutics, Inc. (LYCA)
- Venrock Healthcare Capital Partners III, L.P., 10% Owner
- Versant Ventures VII GP, L.P., 10% Owner
- Fischer Laurent, Director
- Henderson Jane, Director
- RIEFLIN WILLIAM JL, Director
- Staben Steven, Chief Scientific Officer